Pensilvaniya shtatida joylashgan JBS Science bugun Milliy saraton instituti IIB kichik biznes innovatsion tadqiqotlari uchun 3 million dollarlik Bridge mukofotini olganini aytdi. Kompaniya birinchi suyuq biopsiya mahsulotini ishlab chiqdi, bu erta jigar hujayralari saratoni (HCC) uchun siydik DNK skriningidir.
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of jigar saratoni. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating shish DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS, jigar saratoni siydik sinovini rivojlantirish uchun Jon Xopkins universiteti tibbiyot markazidan Jeyms Xemilton va Tomas universiteti kasalxonasidan Xie-Von Xan bilan hamkorlik qilganini aytdi.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
